Children Deserve Medications Adapted to their Needs – Why is Canada Lagging Behind?

Last modified by Doug Maynard on 2019/06/14 02:44

In many cases, children are given adult medications that have been modified for their use. This can be done by either cutting a tablet or crushing it and suspending it in apple juice, or water, for administration. However, because these medications have not been approved by Health Canada there are no data to support how these alterations might affect its efficacy or safety. Development of age appropriate medicines for children requires not only an understanding of their preferences for different formulations, flavours and textures of products but also an understanding of the physiological and biochemical differences between children and adults. Dosing in children may be quite dissimilar to adults due to differences in metabolism depending on the child’s developmental stage.

Oftentimes, pediatric formulations are available in other countries such as the United States and Europe, yet Canadian children do not have access to these child-friendly formulations. The reasons that Canada lags behind in this regard, is that our market is small and the regulatory and reimbursement systems are perceived as complex for companies to market their pediatric products.

The Goodman Pediatric Formulations Centre of the CHU Sainte-Justine is the first of its kind in Canada, and has the mandate to facilitate and promote the development and commercialization of safe and effective medications in a formulation that is specifically adapted for children. The Centre is collaborating with stakeholders to develop more safe and effective pediatric drugs, and to promote practices to increase the safety of medicines administered to children. We invite you to come learn more about what the GPFC is doing to help improve this situation in Canada.

Andrea Gilpin 0984Final A_2 3 Hi Res.jpgDr. Andrea Gilpin

Dr. Gilpin is the General Manager of the Goodman Pediatric Formulations Centre of the CHU Sainte-Justine. Dr. Gilpin began her career as a bench scientist and completed her Doctorate in Molecular Biology and Biochemistry from the University of Toronto. Since that time, her career has brought her through several different roles. She left the lab to obtain an MBA in International Business and then worked for over 12 years in small biotechnology companies. After obtaining her MBA, she started in in business development and moved into investor relations and communications in various small biotechnology companies. She was Vice-President of Investor Relations and Communications at Theratechnologies when she decided, in 2010, to gain pharmaceutical experience and joined the Communications team at Pfizer. In 2012, she took on the role of Head of Corporate Communications for Novartis Canada. With a desire to gain commercial experience, in 2015, she moved to a marketing oncology position in the Lung and Melanoma franchise at Novartis. For more please visit her LinkedIn profile.

Tags:
Created by Andrew Tomayer on 2019/05/09 17:47